Using SELDI-TOF MS to identify serum biomarkers of rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 37, Issue 2, 2008, Pages 94-102

  Liu, W ^a,b   Li, X ^a   Ding, F ^a   Li, Y ^b  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DICLOFENAC; METHOTREXATE; PROTEIN;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TECHNOLOGY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPONDYLITIS, ANKYLOSING;

EID: 42149137437     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701747152     Document Type: Article

References (45)

1. Buckley CD. Science, medicine, and the future. Treatment of rheumatoid arthritis. Br Med J 1997;315:236-8.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
3. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004;63:1079-84.
4. Nikolaisen C, Rekvig OP, Nossent HC. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis. Scand J Rheumatol 2005;34:269-76.
5. Mikkelsen DW, Dodge HJ, Duff IF, Kato H. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. J Chron Dis 1967;20:351-69.
6. Nikolaisen C, Rekvig OP, Nossent HC. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis. Scand J Rheumatol 2007;36:97-100.
7. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005;34:359-66.
8. Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
9. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
10. Carr SA, Hemling ME, Bean MF, Roberts GD. Integration of mass spectrometry in analytical biotechnology. Anal Chem 1991;63:2802-24.
11. Loo JA, Brown J, Critchley G, Mitchell C, Andrews PC, Ogorzalek Loo RR. High sensitivity mass spectrometric methods for obtaining intact molecular weights from gel-separated proteins. Electrophoresis 1999;20:743-8.
12. Zhang W, Czernik AJ, Yungwirth T, Aebersold R, Chait BT. Matrix-assisted laser desorption mass spectrometric peptide mapping of proteins separated by two-dimensional gel electrophoresis: determination of phosphorylation in synapsin I. Protein Sci 1994;3:677-86.
13. von Eggeling F, Davies H, Lomas L, Fiedler W, Junker K, Claussen U, et al. Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. Biotechniques 2000;29:1066-70.
14. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approached for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
15. Weinberger SR, Morris TS, Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics 2000;1:395-416.
16. Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomics 2003;4:463-76.
17. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004;23:34-44.
18. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
19. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003;40:267-79.
20. Koopmann J, Zhang Z, White N, Rosenzweiq J, Fedako N, Jaqannaths S, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
21. Xiao XY, Tang Y, Wei XP, He DC. A preliminary analysis of non-small cell lung cancer biomarkers in serum. Biomed Environ Sci 2003;16:140-8.
22. Wadsworth JT, Somers KD, Stack BC Jr, Cazares L, Malik G, Adam BL. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004;130:98-104.
23. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003;92:223-5.
24. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203-9.
25. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003;3:2310-16.
26. Stanley BA, Gundry RL, Cotter RJ, Van Eyk JE. Heart disease, clinical proteomics and mass spectrometry. Dis Markers 2004;20:167-78.
27. Yip TT, Chan JW, Cho WC, Yip TT, Wang Z, Kwan TL, et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem 2005;51:47-55.
28. Lin HH, Han LY, Cai CZ, et al. Prediction of transporter family from protein sequence by support vector machine approach. Proteins 2006;62:218-31.
29. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis. Advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619-33.
30. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
31. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
32. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971-83.
33. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003;309:18-25.
34. Vlahou A, Schellhammer PF, Medrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-502.
35. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
36. Kaltenhauser S, Pierer M, Arnold S, Kamprad M, Baerwald C, Hantzschel H, et al. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology (Oxford) 2007;46:100-4.
37. Somorjai RL, Dolenko B, Baumgartner R. Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions. Bioinformatics 2003;19:1484-91.
38. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 2000;16:906-14.
39. Byvatov E, Schneider G. Support vector machine applications in bioinformatics. Appl Bioinformatics 2003;2:67-77.
40. Jorissen RN, Gilson MK. Virtual screening of molecular databases using a support vector machine. J Chem Inf Model 2005;45:549-61.
41. Cai CZ, Han LY, Ji ZL, Chen WZ. Enzyme family classification by support vector machines. Proteins 2004;55:66-76.
42. Machold KP, Nell V, Stamm T, Aletaha D, Smolen JS. Early rheumatoid arthritis. Curr Opin Rheumatol 2006;18:282-8.
43. Meyer O, Labarre C, Dougados M, Goupille P, Cantaqrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
44. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizanga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:949-58.
45. de Seny D, Fillet M, Meuwis MA, Geurts P, Lutteri L, Ribbens C, et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum 2005;52:3801-12.